Organon & Co. (NYSE:OGN) Hits New 52-Week Low - What's Next?

Organon & Co. (NYSE:OGN - Get Free Report) shares reached a new 52-week low during trading on Tuesday . The stock traded as low as $10.45 and last traded at $10.67, with a volume of 4492118 shares traded. The stock had previously closed at $11.12.

Analyst Ratings Changes

A number of research analysts have recently commented on OGN shares. Morgan Stanley cut their target price on Organon & Co. from $16.00 to $15.00 and set an "equal weight" rating on the stock in a research note on Wednesday, April 9th. TD Cowen upgraded Organon & Co. to a "hold" rating in a research note on Wednesday, January 15th. Finally, Barclays lowered their target price on shares of Organon & Co. from $26.00 to $24.00 and set an "overweight" rating for the company in a research note on Friday, February 14th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating, two have assigned a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock presently has an average rating of "Hold" and a consensus target price of $20.60.

Organon & Co. Trading Up 0.7 %

The firm has a market capitalization of $3.15 billion, a P/E ratio of 3.67, a price-to-earnings-growth ratio of 0.90 and a beta of 0.73. The stock has a 50-day simple moving average of $13.93 and a two-hundred day simple moving average of $15.22. The company has a current ratio of 1.70, a quick ratio of 1.21 and a debt-to-equity ratio of 17.73.

Organon & Co. (NYSE:OGN - Get Free Report) last issued its earnings results on Thursday, February 13th. The company reported $0.83 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.92 by ($0.09). Organon & Co. had a return on equity of 431.62% and a net margin of 13.49%. The business had revenue of $1.59 billion for the quarter, compared to the consensus estimate of $1.57 billion. On average, equities research analysts anticipate that Organon & Co. will post 3.68 earnings per share for the current year.

Organon & Co. Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Thursday, March 13th. Shareholders of record on Monday, February 24th were issued a dividend of $0.28 per share. The ex-dividend date of this dividend was Monday, February 24th. This represents a $1.12 dividend on an annualized basis and a yield of 9.17%. Organon & Co.'s dividend payout ratio is currently 33.63%.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the stock. Horizon Bancorp Inc. IN grew its stake in Organon & Co. by 2,401.5% in the fourth quarter. Horizon Bancorp Inc. IN now owns 1,651 shares of the company's stock valued at $25,000 after purchasing an additional 1,585 shares during the last quarter. Millstone Evans Group LLC purchased a new position in shares of Organon & Co. in the 4th quarter worth approximately $29,000. Larson Financial Group LLC grew its position in shares of Organon & Co. by 345.4% in the 4th quarter. Larson Financial Group LLC now owns 2,236 shares of the company's stock worth $33,000 after buying an additional 1,734 shares during the last quarter. Riverview Trust Co raised its stake in shares of Organon & Co. by 117.7% during the 4th quarter. Riverview Trust Co now owns 2,390 shares of the company's stock worth $36,000 after acquiring an additional 1,292 shares in the last quarter. Finally, Versant Capital Management Inc lifted its position in Organon & Co. by 92.2% during the fourth quarter. Versant Capital Management Inc now owns 2,760 shares of the company's stock valued at $41,000 after acquiring an additional 1,324 shares during the last quarter. 77.43% of the stock is owned by institutional investors.

About Organon & Co.

Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women's health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.